The decision last week by Novo Nordisk AS to drop its Phase III inhaled-insulin program mildly stung licensor Aradigm Corp., putting observers in mind of Pfizer Inc.'s dump of Exubera in October - a surprise maneuver that dented shares of partner Nektar Therapeutics Inc. - and leaving investors with chips on other, similar efforts waiting to exhale. Stay in or get out? (BioWorld Financial Watch) Read More
